Incyte Corp.

INCY ·Healthcare, Diagnostics & Research, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $5.14B $4.24B $3.70B $3.39B $2.99B $2.67B $2.16B $1.87B
Jakafi Net Product Revenues $2.59B $2.41B $2.13B $1.94B $1.68B $1.39B
Other Net Product Revenues $564.4M $336.5M $187.8M $71.9M $92.6M $79.8M
Royalty Revenues $515.3M $468.4M $490.2M $411.1M $333.8M $263.6M
Milestone and Contract Revenues $22.3M $181.2M $173.6M $250.0M $50.0M $140.0M
Cost of Revenue $372.1M $312.1M $255.0M $207.0M $151.0M $131.3M $114.2M $94.1M
Gross Profit $4.77B $3.93B $3.44B $3.19B $2.84B $2.54B $2.04B $1.78B
Gross Margin 92.8% 92.6% 93.1% 93.9% 94.9% 95.1% 94.7% 95.0%
Operating Expenses
Research & Development $2.05B $2.61B $1.63B $1.59B $1.46B $2.22B $1.15B $1.20B
SG&A Expense $1.38B $1.24B $1.16B $1.00B $739.6M $516.9M $468.7M $434.4M
Operating Income $1.51B $61.4M $620.5M $579.4M $585.8M $-263.7M $402.0M $129.2M
Operating Margin 29.5% 1.4% 16.8% 17.1% 19.6% -9.9% 18.6% 6.9%
Interest Expense $2.6M $2.7M $1.9M $2.2M $1.9M $1.5M
Pretax Income $1.66B $316.6M $834.2M $529.1M $570.4M $-232.2M $486.8M $115.3M
Income Tax Expense $377.8M $284.0M $236.6M $188.5M $-378.1M $63.5M $39.9M $5.9M
Net Income $1.29B $32.6M $597.6M $340.7M $948.6M $-295.7M $446.9M $109.5M
Net Margin 25.0% 0.8% 16.2% 10.0% 31.8% -11.1% 20.7% 5.9%
EPS (Basic) $6.59 $0.16 $2.67 $1.53 $4.30 $-1.36 $2.08 $0.52
EPS (Diluted) $6.41 $0.15 $2.65 $1.52 $4.27 $-1.36 $2.05 $0.51
Shares Outstanding (Basic) 195.2M 207.1M 223.6M 222.0M 220.4M 218.1M 214.9M 212.4M
Shares Outstanding (Diluted) 200.7M 210.5M 225.9M 224.0M 222.1M 218.1M 217.7M 215.6M
Dividends Per Share
← Newer Page 1 of 3 Older →